Eisai To Market Diabetic Neuropathic Pain Drug in China
This article was originally published in PharmAsia News
Executive Summary
Eisai announced July 30 that its China subsidiary Eisai China entered a licensing agreement with Hong Kong-based Health Vision Enterprise, a sales subsidiary of STADA Arzneimittel AG for the sales and repackaging of alpha-lipon 300 STADA (alpha-lipoic acid), a treatment for diabetic neuropathic pain developed by STADA. Eisai China will take over sales promotion activities for the product starting August 1 and will assume repacking and sales rights upon receipt of approval. According to Eisai, diabetes patients in China increase annually by 10 percent and will reach 46 million by 2025. (Click here for more - Japanese language) "Eisai To Market Diabetes Complication Drug In China" - Search China News (7/30/08)